目的：解析复方苦参注射液真实世界治疗淋巴瘤的西药联合应用规律，为淋巴瘤临床合理有效用药提供参考借鉴。方法：以全国范围内22家三甲医院中入院主要诊断为淋巴瘤且使用复方苦参注射液治疗的患者为研究对象，检索中国中医科学院中医临床基础医学研究所建立的，真实世界医院信息系统电子医疗数据大型集成仓库中患者治疗信息，分析西药联合用药频数分布特点，并应用关联规则Apriori算法分析联合用药关联性特征。结果：从数据仓库中共检索到3 674例符合要求患者数据纳入研究。复方苦参注射液临床常与抗 生素类药、糖皮质激素药、5-HT受体阻断药、免疫调节药、质子泵抑制剂、抗肿瘤化疗药、保肝药等西药联用，其联用药物关联规则组合均呈现特定规律，基本符合淋巴瘤诊疗相关指南。结论：复方苦参注射液联用西药治疗淋巴瘤的真实世界临床应用特征，基本符合相关指南，侧重降低化疗副作用、延长生存期、提高生存质量，为其治疗淋巴瘤的临床合理用药提供了参考依据。

This study was aimed to investigate the application rules of Fu- Fang Ku- Shen (FFKS) injection in combination with modern medicines for the treatment of lymphoma in the real world, in order to provide references for rational clinical application of effective medication. Patients diagnosed as lymphoma and treated with FFKS injection from 22 triple-A hospitals in China were enrolled as research objects. Patients’treatment data were extracted from the hospital information system, which was established by the Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, in order to analyze the frequency distribution characteristics of modern medications combined in the treatment. Association rules and Apriori algorithm were used in the analysis of association characteristics of medication combination. The results showed that 3 674 cases fit the inclusion criteria were searched from the data warehouse. In the clinical practice, FFKS injection was frequently combined with modern medications, such as antibiotics, glucocorticoids, 5- HT receptor antagonists, immunomodulatory drugs, proton pump inhibitor, chemotherapeutic drugs, and hepatic protector. Its associated modern medication combination showed special rules, which was in consistency with the related diagnosis and treatment of lymphoma guideline. It was concluded that FFKS injection combined with modern medicine in the treatment of lymphoma in the real world was basically in consistency with related guidelines. It was focused on reducing the side effects of chemotherapy, prolonging survival time, and improving quality of life. It provided references for rational clinical drug application of lymphoma.

国家“重大新药创制”科技重大专项（2015ZX09501004-001-002）：基于监测数据的风险信号评估研究，负责人：谢雁鸣、王连心；国家“重大新 药创制”科技重大专项（2015ZX09501004-001-009）：中药上市后安全性风险信号临床评估及机理研究，负责人：谢雁鸣、王志飞；北京市中医 药科技发展专项（JJ2014-53）：中西药联合应用评价及机制的方法研究，负责人：王连心；中国中医科学院自主选题项目（PY1303）：中药上市后 临床再评价关键技术创新团队，负责人：谢雁鸣。